A weekly summary of Novamind news and media, including a report of our fiscal Q3 financial results and operating highlights.
FEATURES June 4, 2021
Psychedelic Healing,Here and Now
At Novamind, we’re preparing for the future of psychedelic medicine, but we’re also treating people today and the results have been life changing.
“This is the first treatment that’s ever given me any relief from suicidal ideations. It’s like they’re gone.”
FEATURES June 1, 2021
More Than Just a Treatment for Depression
Novamind CMO Reid Robison speaks to the Toronto Sun about why ketamine is a game changer for treating eating disorders.
“I was sitting with people before, during and after treatment and I was blown away by what I saw. It’s not just a treatment for depression.”
FEATURES June 2, 2021
Growing at Scale
Behavioral Healthcare Executive covers our fiscal Q3 earnings report, detailing growth and forecasted clinic visits.
“Novamind, a mental health company that specializes in psychedelic medicine, this week announced revenues of $1.85 million for its fiscal quarter ending March 31, a 43% increase over the prior quarter. With its previously announced plans to open 4 new clinics, doubling the size of its network, between July and September, Novamind said in its earnings report that it expects to increase patient volume to more than 65,000 clinic visits in 2021, which would represent a 225% increase year-over-year.”
Novamind Reports Fiscal Q3 Financial Results and Operating Highlights
“Since listing on the CSE this January, Novamind has demonstrated its ability to rapidly scale access to innovative mental health treatment and psychedelic medicine,” said Yaron Conforti, CEO and Director, Novamind. “The contract with Merck to research a promising new drug, leveraged our expertise in patient recruitment and patient management. Novamind will continue to execute on its aggressive growth initiatives in 2021, further expanding organically and through acquisitions ahead of the FDA’s anticipated approvals of MDMA and psilocybin.”
June 1, 2021
Researchers to Hone In On Most Therapeutic Doses of LSD
Identifying the correct dose for therapeutic settings is a crucial step in the path towards optimizing the healing power of psychedelics. In this article, Psychedelic Spotlight details new research studying the optimal LSD dosage for the treatment of mental health disorders. We look forward to more research and clinical trials in the future and will prepare for the time when LSD can be used as a treatment option in our clinics.
The psychologists signing up for psychedelic therapy training: ‘Amazing things can happen’
The promise of psychedelic medicine is too great to ignore for Campbell Townsend, an Australian-based psychologist who is training in psychedelic-assisted psychotherapy. The Australian government has recently committed $15m to psychedelic clinical trials and support is growing in that country. There is significant momentum growing. Staying at the forefront of psychedelic research, Novamind is currently developing protocols for ketamine-assisted psychotherapy that will standardize and provide best-practice treatment methods for the widespread use of psychedelic medicine.
Follow @novamind_inc on Instagram
For further information, contact:
Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]
Tags: COMPASS PATHWAYS, CSE, Field Trip Health Ltd., ketamine, mental health, MIND MEDICINE (MINDMED) INC, small cap